Breast Neoplasms Clinical Trial
— IESOfficial title:
Randomized Double-Blind Trial In Postmenopausal Women With Primary Breast Cancer Who Have Received Adjuvant Tamoxifen For 2-3 Years, Comparing Subsequent Adjuvant Exemestane Treatment With Further Tamoxifen
| Verified date | April 2014 |
| Source | Pfizer |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United States: Food and Drug Administration |
| Study type | Interventional |
To compare the sequential administration of exemestane with administration of further tamoxifen until 5 years in postmenopausal women with operable breast cancer who have already received 2-3 years of adjuvant tamoxifen, in terms of disease-free survival (DFS), overall survival (OS), incidence of contralateral breast cancer and long-term tolerability.
| Status | Completed |
| Enrollment | 4740 |
| Est. completion date | March 2013 |
| Est. primary completion date | June 2003 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 30 Years and older |
| Eligibility |
Inclusion Criteria: - postmenopausal women with histologically or cytologically confirmed primary breast adenocarcinoma, receiving tamoxifen and have been treated with tamoxifen continuously for between 2 and 3 years and one month, and still free of disease Exclusion Criteria: - unresectable breast cancer - ER negative primary tumor |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Argentina | Pfizer Investigational Site | Buenos Aires | Capital Federal |
| Argentina | Pfizer Investigational Site | Buenos Aires | Capital Federal |
| Argentina | Pfizer Investigational Site | Buenos Aires | Capital Federal |
| Argentina | Pfizer Investigational Site | Buenos Aires | Capital Federal |
| Argentina | Pfizer Investigational Site | Buenos Aires | Capital Federal |
| Argentina | Pfizer Investigational Site | Buenos Aires | |
| Argentina | Pfizer Investigational Site | Cordoba | |
| Argentina | Pfizer Investigational Site | Haedo | Buenos Aires |
| Argentina | Pfizer Investigational Site | Rosario | Santa Fe |
| Argentina | Pfizer Investigational Site | Rosario 2000 | Pcia. de Santa Fe |
| Argentina | Pfizer Investigational Site | San Isidro | Buenos Aires |
| Argentina | Pfizer Investigational Site | San Martin | Buenos Aires |
| Australia | Pfizer Investigational Site | Adelaide | South Australia |
| Australia | Pfizer Investigational Site | Bendigo | Victoria |
| Australia | Pfizer Investigational Site | Box Hill | Victoria |
| Australia | Pfizer Investigational Site | Camperdown | New South Wales |
| Australia | Pfizer Investigational Site | Dubbo | New South Wales |
| Australia | Pfizer Investigational Site | Liverpool | New South Wales |
| Australia | Pfizer Investigational Site | Ringwood East | Victoria |
| Australia | Pfizer Investigational Site | Waratah | New South Wales |
| Belgium | Pfizer Investigational Site | Antwerpen | |
| Belgium | Pfizer Investigational Site | Arlon | |
| Belgium | Pfizer Investigational Site | Baudour | |
| Belgium | Pfizer Investigational Site | Brasschaat | |
| Belgium | Pfizer Investigational Site | Bruxelles | |
| Belgium | Pfizer Investigational Site | Bruxelles | |
| Belgium | Pfizer Investigational Site | Charleroi | |
| Belgium | Pfizer Investigational Site | Edegem | |
| Belgium | Pfizer Investigational Site | Genk | |
| Belgium | Pfizer Investigational Site | Haine St. Paul | |
| Belgium | Pfizer Investigational Site | Hasselt | |
| Belgium | Pfizer Investigational Site | Kraainem | |
| Belgium | Pfizer Investigational Site | La Louviere | |
| Belgium | Pfizer Investigational Site | Leuven | |
| Belgium | Pfizer Investigational Site | Liege | |
| Belgium | Pfizer Investigational Site | Merksem | |
| Belgium | Pfizer Investigational Site | Namur | |
| Belgium | Pfizer Investigational Site | Verviers | |
| Belgium | Pfizer Investigational Site | Wilrijk | |
| Bosnia and Herzegovina | Pfizer Investigational Site | Sarajevo | |
| Bulgaria | Pfizer Investigational Site | Plovdiv | |
| Bulgaria | Pfizer Investigational Site | Sofia | |
| Bulgaria | Pfizer Investigational Site | Sofia | |
| Bulgaria | Pfizer Investigational Site | Sofia | |
| Bulgaria | Pfizer Investigational Site | Stara Zagora | |
| Croatia | Pfizer Investigational Site | Osijek | |
| Croatia | Pfizer Investigational Site | Split | |
| Croatia | Pfizer Investigational Site | Zagreb | |
| Croatia | Pfizer Investigational Site | Zagreb | |
| Czech Republic | Pfizer Investigational Site | Brno | |
| Czech Republic | Pfizer Investigational Site | Ceske Budejovice | |
| Czech Republic | Pfizer Investigational Site | Prague 2 | |
| Denmark | Pfizer Investigational Site | Aarhus C | |
| Denmark | Pfizer Investigational Site | Esbjerg | |
| Denmark | Pfizer Investigational Site | Herlev | |
| Denmark | Pfizer Investigational Site | Herning | |
| Denmark | Pfizer Investigational Site | Hilleroed | |
| Denmark | Pfizer Investigational Site | Koebenhavn OE | |
| Denmark | Pfizer Investigational Site | Naestved | |
| Denmark | Pfizer Investigational Site | Roskilde | |
| Denmark | Pfizer Investigational Site | Vejle | |
| Denmark | Pfizer Investigational Site | Viborg | |
| Egypt | Pfizer Investigational Site | Cairo | |
| Estonia | Pfizer Investigational Site | Tartu | |
| France | Pfizer Investigational Site | Angers | |
| France | Pfizer Investigational Site | Annecy Cedex | |
| France | Pfizer Investigational Site | Avignon Cedex 2 | |
| France | Pfizer Investigational Site | Bordeaux | |
| France | Pfizer Investigational Site | Bordeaux | |
| France | Pfizer Investigational Site | Brest | |
| France | Pfizer Investigational Site | Caen | |
| France | Pfizer Investigational Site | Caen Cedex 05 | |
| France | Pfizer Investigational Site | Clermont Ferrand | |
| France | Pfizer Investigational Site | Evreux | |
| France | Pfizer Investigational Site | Lagny Sur Marne | |
| France | Pfizer Investigational Site | Le Havre | |
| France | Pfizer Investigational Site | Le Mans | |
| France | Pfizer Investigational Site | Lille | |
| France | Pfizer Investigational Site | Lyon | |
| France | Pfizer Investigational Site | Marseille | |
| France | Pfizer Investigational Site | Meaux | |
| France | Pfizer Investigational Site | Montbeliard | |
| France | Pfizer Investigational Site | Mulhouse | |
| France | Pfizer Investigational Site | Nice | |
| France | Pfizer Investigational Site | Paris | |
| France | Pfizer Investigational Site | Paris | |
| France | Pfizer Investigational Site | Perpignan | |
| France | Pfizer Investigational Site | Rennes | |
| France | Pfizer Investigational Site | Rouen | |
| France | Pfizer Investigational Site | Saint-Herblain | |
| France | Pfizer Investigational Site | St Cloud | |
| France | Pfizer Investigational Site | Strasbourg | |
| France | Pfizer Investigational Site | Toulouse | |
| Germany | Pfizer Investigational Site | Berlin | |
| Germany | Pfizer Investigational Site | Berlin | |
| Germany | Pfizer Investigational Site | Chemnitz | |
| Germany | Pfizer Investigational Site | Erlangen | |
| Germany | Pfizer Investigational Site | Freiburg | |
| Germany | Pfizer Investigational Site | Gera | |
| Germany | Pfizer Investigational Site | Greiz | |
| Germany | Pfizer Investigational Site | Halle | |
| Germany | Pfizer Investigational Site | Halle | |
| Germany | Pfizer Investigational Site | Hamburg | |
| Germany | Pfizer Investigational Site | Hildburghausen | |
| Germany | Pfizer Investigational Site | Leipzig | |
| Germany | Pfizer Investigational Site | Luebeck | |
| Germany | Pfizer Investigational Site | Muenchen | |
| Germany | Pfizer Investigational Site | Riesa | |
| Germany | Pfizer Investigational Site | Rodewisch | |
| Germany | Pfizer Investigational Site | Saarbruecken | |
| Germany | Pfizer Investigational Site | Suhl | |
| Germany | Pfizer Investigational Site | Weiden | |
| Greece | Pfizer Investigational Site | Athens | Attiki |
| Greece | Pfizer Investigational Site | Athens | Attiki |
| Greece | Pfizer Investigational Site | Heraklion | Crete |
| Hong Kong | Pfizer Investigational Site | New Territories | |
| Hungary | Pfizer Investigational Site | Budapest | |
| Hungary | Pfizer Investigational Site | Budapest | |
| Hungary | Pfizer Investigational Site | Budapest | |
| Ireland | Pfizer Investigational Site | Cork | |
| Ireland | Pfizer Investigational Site | Cork, Ireland | |
| Ireland | Pfizer Investigational Site | Dublin | |
| Ireland | Pfizer Investigational Site | Dublin 9 | |
| Ireland | Pfizer Investigational Site | Galway | |
| Israel | Pfizer Investigational Site | Haifa | |
| Israel | Pfizer Investigational Site | Haifa | |
| Israel | Pfizer Investigational Site | Jerusalem | |
| Israel | Pfizer Investigational Site | Jerusalem | |
| Israel | Pfizer Investigational Site | Kfar Saba | |
| Israel | Pfizer Investigational Site | Petah Tikva | |
| Israel | Pfizer Investigational Site | Rehovot | |
| Italy | Pfizer Investigational Site | Alba (CN) | |
| Italy | Pfizer Investigational Site | Aviano (PN) | |
| Italy | Pfizer Investigational Site | Bergamo | |
| Italy | Pfizer Investigational Site | Biella | |
| Italy | Pfizer Investigational Site | Cagliari | |
| Italy | Pfizer Investigational Site | Carpi | Modena |
| Italy | Pfizer Investigational Site | Casale Monferrato, AL | |
| Italy | Pfizer Investigational Site | Correggio | |
| Italy | Pfizer Investigational Site | Cremona | |
| Italy | Pfizer Investigational Site | Cuneo | |
| Italy | Pfizer Investigational Site | Fermo FM | |
| Italy | Pfizer Investigational Site | Firenze | |
| Italy | Pfizer Investigational Site | Genova | |
| Italy | Pfizer Investigational Site | Genova | |
| Italy | Pfizer Investigational Site | Lecco | |
| Italy | Pfizer Investigational Site | Lodi | |
| Italy | Pfizer Investigational Site | Mantova | |
| Italy | Pfizer Investigational Site | Milano | |
| Italy | Pfizer Investigational Site | Milano | |
| Italy | Pfizer Investigational Site | Milano | |
| Italy | Pfizer Investigational Site | Milano | |
| Italy | Pfizer Investigational Site | Modena | |
| Italy | Pfizer Investigational Site | Monserrato (CA) | |
| Italy | Pfizer Investigational Site | Monza | |
| Italy | Pfizer Investigational Site | Napoli | |
| Italy | Pfizer Investigational Site | Palermo | |
| Italy | Pfizer Investigational Site | Parma | |
| Italy | Pfizer Investigational Site | Perugia | |
| Italy | Pfizer Investigational Site | Piacenza | |
| Italy | Pfizer Investigational Site | Pietra Ligure (SV) | |
| Italy | Pfizer Investigational Site | Pisa | |
| Italy | Pfizer Investigational Site | Reggio Emilia | |
| Italy | Pfizer Investigational Site | Roma | |
| Italy | Pfizer Investigational Site | Sassari | |
| Italy | Pfizer Investigational Site | Terni | |
| Italy | Pfizer Investigational Site | Thiene (VI) | |
| Italy | Pfizer Investigational Site | Torino | |
| Italy | Pfizer Investigational Site | Tortona | |
| Italy | Pfizer Investigational Site | Trescore Balneario BG | |
| Italy | Pfizer Investigational Site | Treviglio (BG) | |
| Italy | Pfizer Investigational Site | Varese | |
| Luxembourg | Pfizer Investigational Site | Luxembourg | |
| Malta | Pfizer Investigational Site | Floriana | |
| Netherlands | Pfizer Investigational Site | Amersfoort | |
| Netherlands | Pfizer Investigational Site | Amsterdam | |
| Netherlands | Pfizer Investigational Site | Amsterdam | |
| Netherlands | Pfizer Investigational Site | Amsterdam | |
| Netherlands | Pfizer Investigational Site | Apeldoorn | |
| Netherlands | Pfizer Investigational Site | Blaricum | |
| Netherlands | Pfizer Investigational Site | Breda | |
| Netherlands | Pfizer Investigational Site | Delft | |
| Netherlands | Pfizer Investigational Site | Den Haag | |
| Netherlands | Pfizer Investigational Site | Eindhoven | |
| Netherlands | Pfizer Investigational Site | Enschede | |
| Netherlands | Pfizer Investigational Site | Groningen | |
| Netherlands | Pfizer Investigational Site | Groningen | |
| Netherlands | Pfizer Investigational Site | Hengelo | |
| Netherlands | Pfizer Investigational Site | Leeuwarden | |
| Netherlands | Pfizer Investigational Site | Leiden | |
| Netherlands | Pfizer Investigational Site | Leidschendam | |
| Netherlands | Pfizer Investigational Site | Podybus 90153 | |
| Netherlands | Pfizer Investigational Site | Roermond | |
| Netherlands | Pfizer Investigational Site | Sittard | |
| Netherlands | Pfizer Investigational Site | Utrecht | |
| Netherlands | Pfizer Investigational Site | Veldhoven | |
| Netherlands | Pfizer Investigational Site | Zaandam | |
| New Zealand | Pfizer Investigational Site | Auckland | |
| New Zealand | Pfizer Investigational Site | Hamilton | Waikato |
| Norway | Pfizer Investigational Site | Bergen | |
| Norway | Pfizer Investigational Site | Bodo | |
| Norway | Pfizer Investigational Site | Fredrikstad | |
| Norway | Pfizer Investigational Site | Haugesund | |
| Norway | Pfizer Investigational Site | Levanger | |
| Norway | Pfizer Investigational Site | Mo i Rana | |
| Norway | Pfizer Investigational Site | Molde | |
| Norway | Pfizer Investigational Site | Notodden | |
| Norway | Pfizer Investigational Site | Oslo | |
| Norway | Pfizer Investigational Site | Rissa | |
| Norway | Pfizer Investigational Site | Rjukan | |
| Norway | Pfizer Investigational Site | Sandefjord | |
| Norway | Pfizer Investigational Site | Tonsberg | |
| Norway | Pfizer Investigational Site | Tromso | |
| Norway | Pfizer Investigational Site | Tromsø | |
| Peru | Pfizer Investigational Site | Lima | |
| Poland | Pfizer Investigational Site | Gdansk | |
| Poland | Pfizer Investigational Site | Gliwice | |
| Poland | Pfizer Investigational Site | Krakow | |
| Poland | Pfizer Investigational Site | Krakow | |
| Poland | Pfizer Investigational Site | Lodz | |
| Poland | Pfizer Investigational Site | Opole | |
| Poland | Pfizer Investigational Site | Poznan | |
| Poland | Pfizer Investigational Site | Sopot | |
| Poland | Pfizer Investigational Site | Warszawa | |
| Portugal | Pfizer Investigational Site | Coimbra | |
| Portugal | Pfizer Investigational Site | Coimbra | |
| Portugal | Pfizer Investigational Site | Evora | |
| Romania | Pfizer Investigational Site | Bucuresti | |
| Romania | Pfizer Investigational Site | Cluj Napoca | |
| Romania | Pfizer Investigational Site | Timisoara | |
| Russian Federation | Pfizer Investigational Site | St. Petersburg | |
| Serbia | Pfizer Investigational Site | Belgrade | |
| Serbia | Pfizer Investigational Site | Sremska Kamenica | |
| Slovakia | Pfizer Investigational Site | Banska Bystrica | |
| Slovakia | Pfizer Investigational Site | Bratislava | |
| Slovakia | Pfizer Investigational Site | Kosice | |
| Slovenia | Pfizer Investigational Site | Ljubljana | |
| South Africa | Pfizer Investigational Site | Johannesburg | Gauteng |
| South Africa | Pfizer Investigational Site | Observatory | |
| Spain | Pfizer Investigational Site | Albacete | |
| Spain | Pfizer Investigational Site | Alcoy | Alicante |
| Spain | Pfizer Investigational Site | Alicante | |
| Spain | Pfizer Investigational Site | Badajoz | |
| Spain | Pfizer Investigational Site | Badajoz | |
| Spain | Pfizer Investigational Site | Badalona | Barcelona |
| Spain | Pfizer Investigational Site | Badalona | Barcelona |
| Spain | Pfizer Investigational Site | Barbastro | Huesca |
| Spain | Pfizer Investigational Site | Cordoba | |
| Spain | Pfizer Investigational Site | Elche | Alicante |
| Spain | Pfizer Investigational Site | Guadalajara | |
| Spain | Pfizer Investigational Site | Lleida | |
| Spain | Pfizer Investigational Site | Madrid | |
| Spain | Pfizer Investigational Site | Madrid | |
| Spain | Pfizer Investigational Site | Madrid | |
| Spain | Pfizer Investigational Site | Reus | Tarragona |
| Spain | Pfizer Investigational Site | San Juan de Alicante | Alicante |
| Spain | Pfizer Investigational Site | San Sebastian | Guipuzcoa |
| Spain | Pfizer Investigational Site | Sant Joan D'Alacant | Alicante |
| Spain | Pfizer Investigational Site | Terrassa | Barcelona |
| Spain | Pfizer Investigational Site | Terrassa | Barcelona |
| Spain | Pfizer Investigational Site | Valencia | |
| Spain | Pfizer Investigational Site | Zaragoza | |
| Sweden | Pfizer Investigational Site | Boras | |
| Sweden | Pfizer Investigational Site | Borås | |
| Sweden | Pfizer Investigational Site | Goteborg | |
| Sweden | Pfizer Investigational Site | Halmstad | |
| Sweden | Pfizer Investigational Site | Helsingborg | |
| Sweden | Pfizer Investigational Site | Kristianstad | |
| Sweden | Pfizer Investigational Site | Linkoping | |
| Sweden | Pfizer Investigational Site | Lund | |
| Sweden | Pfizer Investigational Site | Malmo | |
| Sweden | Pfizer Investigational Site | Motala | |
| Sweden | Pfizer Investigational Site | Nässjö | |
| Sweden | Pfizer Investigational Site | Norrkoping | |
| Sweden | Pfizer Investigational Site | Varnamo | |
| Sweden | Pfizer Investigational Site | Vasteras | |
| Sweden | Pfizer Investigational Site | Vastervik | |
| Sweden | Pfizer Investigational Site | Vaxjo | |
| Switzerland | Pfizer Investigational Site | Basel | |
| Switzerland | Pfizer Investigational Site | Bellinzona | |
| Switzerland | Pfizer Investigational Site | Bern | |
| Switzerland | Pfizer Investigational Site | Bern | |
| Switzerland | Pfizer Investigational Site | Genève | |
| United Kingdom | Pfizer Investigational Site | Bangor | Gwynedd |
| United Kingdom | Pfizer Investigational Site | Belfast | |
| United Kingdom | Pfizer Investigational Site | Bournemouth | Dorset |
| United Kingdom | Pfizer Investigational Site | Bradford | |
| United Kingdom | Pfizer Investigational Site | Bristol | |
| United Kingdom | Pfizer Investigational Site | Cardiff | |
| United Kingdom | Pfizer Investigational Site | Coventry | |
| United Kingdom | Pfizer Investigational Site | East Kilbride | |
| United Kingdom | Pfizer Investigational Site | Epping | Essex |
| United Kingdom | Pfizer Investigational Site | Gosport | Hants |
| United Kingdom | Pfizer Investigational Site | Harrogate | N. Yorkshire |
| United Kingdom | Pfizer Investigational Site | Huddersfield | |
| United Kingdom | Pfizer Investigational Site | Hull | East Yorkshire |
| United Kingdom | Pfizer Investigational Site | Huntingdon | Cambs |
| United Kingdom | Pfizer Investigational Site | Leeds | |
| United Kingdom | Pfizer Investigational Site | Leeds | |
| United Kingdom | Pfizer Investigational Site | Lincoln | |
| United Kingdom | Pfizer Investigational Site | London | |
| United Kingdom | Pfizer Investigational Site | London | |
| United Kingdom | Pfizer Investigational Site | London | |
| United Kingdom | Pfizer Investigational Site | London | |
| United Kingdom | Pfizer Investigational Site | London | |
| United Kingdom | Pfizer Investigational Site | Londonderry | N. Ireland |
| United Kingdom | Pfizer Investigational Site | Luton | |
| United Kingdom | Pfizer Investigational Site | Manchester | |
| United Kingdom | Pfizer Investigational Site | Newport | Gwent |
| United Kingdom | Pfizer Investigational Site | Northwood | Middlesex |
| United Kingdom | Pfizer Investigational Site | Salterhebble | Halifax |
| United Kingdom | Pfizer Investigational Site | Sheffield | |
| United Kingdom | Pfizer Investigational Site | Shrewsbury | |
| United Kingdom | Pfizer Investigational Site | Somerset | |
| United Kingdom | Pfizer Investigational Site | Southampton | |
| United Kingdom | Pfizer Investigational Site | Steeton | |
| United Kingdom | Pfizer Investigational Site | Stoke on Trent | |
| United Kingdom | Pfizer Investigational Site | Swansea | South Wales |
| United Kingdom | Pfizer Investigational Site | Taunton | Somerset |
| United Kingdom | Pfizer Investigational Site | Telford | |
| United Kingdom | Pfizer Investigational Site | Westcliff-On-Sea | Essex |
| United Kingdom | Pfizer Investigational Site | Wythenshawe, Manchester | |
| United Kingdom | Pfizer Investigational Site | York | Yorkshire |
| United States | Pfizer Investigational Site | Albany | New York |
| United States | Pfizer Investigational Site | Arlington | Texas |
| United States | Pfizer Investigational Site | Bedford | Texas |
| United States | Pfizer Investigational Site | Birmingham | Alabama |
| United States | Pfizer Investigational Site | Birmingham | Alabama |
| United States | Pfizer Investigational Site | Birmingham | Alabama |
| United States | Pfizer Investigational Site | Boulder | Colorado |
| United States | Pfizer Investigational Site | Cedar Rapids | Iowa |
| United States | Pfizer Investigational Site | Colorado Springs | Colorado |
| United States | Pfizer Investigational Site | Dallas | Texas |
| United States | Pfizer Investigational Site | Dallas | Texas |
| United States | Pfizer Investigational Site | Dallas | Texas |
| United States | Pfizer Investigational Site | Denver | Colorado |
| United States | Pfizer Investigational Site | El Paso | Texas |
| United States | Pfizer Investigational Site | El Paso | Texas |
| United States | Pfizer Investigational Site | Fishers | Indiana |
| United States | Pfizer Investigational Site | Fishers | Indiana |
| United States | Pfizer Investigational Site | Fort Collins | Colorado |
| United States | Pfizer Investigational Site | Garland | Texas |
| United States | Pfizer Investigational Site | Green Valley | Arizona |
| United States | Pfizer Investigational Site | Green Velley | Arizona |
| United States | Pfizer Investigational Site | Houston | Texas |
| United States | Pfizer Investigational Site | Houston | Texas |
| United States | Pfizer Investigational Site | Houston | Texas |
| United States | Pfizer Investigational Site | Houston | Texas |
| United States | Pfizer Investigational Site | Indianapolis | Indiana |
| United States | Pfizer Investigational Site | Indianapolis | Indiana |
| United States | Pfizer Investigational Site | Indianapolis | Indiana |
| United States | Pfizer Investigational Site | Jacksonville | Florida |
| United States | Pfizer Investigational Site | Jacksonville | Florida |
| United States | Pfizer Investigational Site | Jacksonville Beach | Florida |
| United States | Pfizer Investigational Site | Lakewood | Colorado |
| United States | Pfizer Investigational Site | Latham | New York |
| United States | Pfizer Investigational Site | Longview | Texas |
| United States | Pfizer Investigational Site | McAllen | Texas |
| United States | Pfizer Investigational Site | Mesquite | Texas |
| United States | Pfizer Investigational Site | Ocala | Florida |
| United States | Pfizer Investigational Site | Odessa | Texas |
| United States | Pfizer Investigational Site | Orange Park | Florida |
| United States | Pfizer Investigational Site | Pasadena | Texas |
| United States | Pfizer Investigational Site | Pittsfield | Massachusetts |
| United States | Pfizer Investigational Site | Plano | Texas |
| United States | Pfizer Investigational Site | Portland | Oregon |
| United States | Pfizer Investigational Site | Portland | Oregon |
| United States | Pfizer Investigational Site | San Antonio | Texas |
| United States | Pfizer Investigational Site | Sherman | Texas |
| United States | Pfizer Investigational Site | Spokane | Washington |
| United States | Pfizer Investigational Site | Spokane | Washington |
| United States | Pfizer Investigational Site | Sugar Land | Texas |
| United States | Pfizer Investigational Site | Thornton | Colorado |
| United States | Pfizer Investigational Site | Tucson | Arizona |
| United States | Pfizer Investigational Site | Tucson | Arizona |
| United States | Pfizer Investigational Site | Tucson | Arizona |
| United States | Pfizer Investigational Site | Tucson | Arizona |
| United States | Pfizer Investigational Site | Tucson | Arizona |
| United States | Pfizer Investigational Site | Tyler | Texas |
| United States | Pfizer Investigational Site | Weslaco | Texas |
| Lead Sponsor | Collaborator |
|---|---|
| Pfizer | International Collaborative Cancer Group (ICCG) |
United States, Argentina, Australia, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Luxembourg, Malta, Netherlands, New Zealand, Norway, Peru, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Disease-Free Survival (DFS) at Month 36 Post-Randomization: Main Study | DFS defined as time from randomization to earliest documentation of breast cancer relapse or death from any cause. DFS at Month 36 post-randomization was defined as probability of participants alive and disease-free at 36 months after the randomization. Participants withdrawn from the study for any reason in the absence of relapse were censored at the date they were last seen. Relapse was categorized as follows: loco-regional: ipsilateral breast or axillary nodal relapse; distant: distant relapse, including supraclavicular nodes; second primary breast cancer: contralateral breast cancer, excluding ductal carcinoma in situ. | Baseline up to Month 36 | No |
| Secondary | Overall Survival (OS) at Month 36 Post-Randomization: Main Study | OS was defined as the duration from randomization to death (due to any cause). OS at Month 36 post-randomization was defined as probability of participants' survival at 36 months after the randomization. For participants who were alive, OS was censored at the last available assessment. Probability of OS at Month 36 post-randomization was reported using Kaplan-Meier estimates at Month 36 post-randomization based on 120-month follow-up data. | Baseline up to Month 120 | No |
| Secondary | Number of Events of Second Breast Cancer in Contralateral Breast: Main Study | Number of events of second primary breast cancer in contralateral breast (excluding ductal carcinoma in situ) were reported. | Baseline up to Month 120 | No |
| Secondary | Percent Change From Baseline in Lumbar Spine and Proximal Femur (Total Hip) Bone Mineral Density (BMD) at 6, 12, 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study | BMD measurements for Lumbar spine (LS) and Proximal Femur (Total Hip [TH]) were performed using dual energy X-ray absorptiometry (DXA) for participants who entered the bone-metabolism sub-study. 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively. | Baseline, 6, 12, 24 months after randomization (on-treatment), 24 months post-treatment | Yes |
| Secondary | Percent Change From Baseline in Femoral Neck and Femoral Wards Bone Mineral Density (BMD) at 6, 12 and 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study | BMD measurements for femoral neck (FN) and femoral wards (FW) were performed using dual energy X-ray absorptiometry (DXA) for participants who entered the bone-metabolism sub-study. 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively. | Baseline, 6, 12, 24 months after randomization (on-treatment), 24 months post-treatment | Yes |
| Secondary | Change From Baseline in Lumbar Spine and Proximal Femur (Total Hip) Bone Mineral Density (BMD) T-scores at 6, 12 and 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study | BMD measurements for Lumbar spine (LS) and Proximal Femur (Total Hip [TH]) were performed using dual energy X-ray absorptiometry (DXA) for participants who entered the bone-metabolism sub-study. Results were scored as T-score. T-score indicated how many standard deviations higher or lower participant's value was when compared to the young normal reference mean. Using the World Health Organization (WHO) criteria for osteoporosis, a T-score of greater than or equal to (>=)-1.0 was classified as normal, a T-score of greater than -2.5 to less than -1.0 as osteopenic, and a T-score less than or equal to (<=)-2.5 as osteoporotic. Here 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively. | Baseline, 6, 12, 24 months after randomization (on-treatment), 24 months post-treatment | Yes |
| Secondary | Percentage of Bone Specific Alkaline Phosphatase (BAP) Serum Concentration Relative to Baseline: Bone Metabolism Sub-study | Bone specific alkaline phosphatase (BAP) serum concentration analyzed using enzyme immuno assay (EIA) at post-baseline time points was expressed as percentage of baseline BAP serum concentration. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively. | Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment | Yes |
| Secondary | Percentage of C-Terminal Telopeptide (CTX) Serum Concentration Relative to Baseline: Bone Metabolism Sub-study | C-terminal telopeptide (CTX) serum concentration analyzed using competitive enzyme-linked immunosorbent assay (ELISA) at post-baseline time points was expressed as percentage of baseline CTX serum concentration. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively. | Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment | Yes |
| Secondary | Percentage of Osteocalcin (OC) and Procollagen T1 C-Peptide (PICP) Serum Concentration Relative to Baseline: Bone Metabolism Sub-study | Osteocalcin (OC) serum concentration analyzed using ELISA and procollagen T1 c-peptide (PICP) serum concentration analyzed using sandwich EIA at post-baseline time points was expressed as percentage of baseline OC serum concentration and baseline PICP serum concentration, respectively. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points, for each group respectively. | Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment | Yes |
| Secondary | Percentage of Deoxy-pyridinoline (DPD) Urine Concentration Relative to Baseline: Bone Metabolism Sub-study | Deoxy-pyridinoline (DPD) urine concentration (adjusted for urinary creatinine) analyzed using competitive EIA at post-baseline time points was expressed as percentage of baseline DPD urine concentration. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively. | Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment | Yes |
| Secondary | Percentage of N-telopeptide of Type 1 Collagen (NTX) Urine Concentration Relative to Baseline: Bone Metabolism Sub-study | N-telopeptide of Type 1 collagen (NTX) urine concentration (adjusted for urinary creatinine) analyzed using competitive inhibition EIA at post-baseline time points was expressed as percentage of baseline NTX urine concentration. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively. | Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment | No |
| Secondary | Number of Participants With Fracture: Bone Metabolism Sub-study | Baseline up to 24 months post-treatment | Yes | |
| Secondary | Change From Baseline in Treatment Outcome Index (TOI) at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study | The TOI was defined as the sum of 23 items based on following Functional Assessment of Cancer Therapy - Breast version [FACT-B] subscales: Physical well-being (7 items), Functional well-being (7 items), Breast cancer subscale (9 items). Each item was scaled from 0='Not at all' to 4='Very much'. Total TOI score ranged from 0 to 92, where higher TOI score indicated better health-related quality of life (QoL). A change of five points in the TOI scores was considered clinically meaningful. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively. Results for 30, 36, 48, 60 months were not reported because data for these time points was only summarized as graphical presentation. | Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization | No |
| Secondary | Change From Baseline in Functional Assessment of Cancer Therapy - Endocrine Subscale (FACT-ES) Total Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study | The FACT-ES assessed health-related QoL in participants with breast cancer. ES subscale comprised of 18 items (hot flushes,cold sweats,night sweats, vaginal discharge,vaginal irritation,vaginal bleeding,vaginal dryness,discomfort with intercourse,lost interest in sex,gained weight,light headed/dizzy,vomiting,had diarrhea,headaches,felt bloated,breast tenderness,mood swings, felt irritable).Participants indicated how true a statement was for them using a 5-point scale from 0 (not at all) to 4 (very much). For items that were negatively framed, the scores were reversed for the analysis so that higher scores equated to a good QoL. Total FACT-ES score was calculated as sum of all the 18 items and ranged from 0 to 72, where higher score indicated better QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively. | Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization | No |
| Secondary | Change From Baseline in Total Functional Assessment of Cancer Therapy - General Breast and Endocrine (FACT-GBE) Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study | FACT-GBE assessed health-related quality of life (QoL) in participants with breast cancer. It consisted of 56 items,summarized to 7 subscales(subscale 1 to 6 constituted total FACT-B and subscale 7 constituted total ES):physical well-being(7 items), social/family well-being(7 items),relationship with doctor (2 items),emotional well-being(6 items),functional well-being(7 items),breast cancer subscale(9 items),endocrine symptoms(18 items). Participants indicated how true a statement had been for them using 5-point scale from 0(not at all) to 4(very much). For items that were negatively framed,scores were reversed for analysis so that higher scores equated to good QoL. Total FACT-GBE score=sum of all 56 items(range 0 to 224, where higher score indicated better QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively. | Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization | Yes |
| Secondary | Change From Baseline in Physical Well-Being (PWB) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study | The PWB subscale assessed physical well-being related QoL in participants with breast cancer. PWB subscale comprised of 7 items (energy lack, nausea, family needs, pain, side effects, felt ill, forced to stay in bed). Participants indicated how true a statement had been for them using a 5-point scale from 0 (not at all) to 4 (very much). For items that were negatively framed, the scores were reversed for the analysis so that higher scores equated to a good QoL. Total PWB score was calculated as the sum of all the 7 items and ranged from 0 to 28, where higher score indicated better physical well-being related QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively. | Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization | No |
| Secondary | Change From Baseline in Social/Family Well-Being (SWB) Sub-scale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study | The SWB subscale assessed social/family well-being related QoL in participants with breast cancer. SWB subscale comprised of 7 items (distant from friends, emotional support, support from friends, family acceptance, family communication, close to main support, sexual satisfaction). Participants indicated how true a statement had been for them using a 5-point scale from 0 (not at all) to 4 (very much). For items that were negatively framed, the scores were reversed for the analysis so that higher scores equated to a good QoL. Total SWB score was calculated as the sum of all the 7 items and ranged from 0 to 28, where higher score indicated better social/family well-being related QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively. | Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization | No |
| Secondary | Change From Baseline in Relationship With Doctor (RWD) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Substudy | The RWD subscale assessed relationship with doctor in participants with breast cancer. RWD subscale comprised of 2 items (confidence in doctors, doctor answered questions). Participants indicated how true a statement had been for them using a 5-point scale from 0 (not at all) to 4 (very much). Total RWD score was calculated as the sum of the 2 items and ranged from 0 to 8, where higher score indicated better relationship with doctor. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively. | Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization | No |
| Secondary | Change From Baseline in Emotional Well-Being (EWB) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study | The EWB subscale assessed emotional well-being related QoL in participants with breast cancer. EWB subscale comprised of 6 items (felt sad, proud of coping, lost hope, felt nervous, worried about dying, worried about condition worsening). Participants indicated how true a statement had been for them using a 5-point scale from 0 (not at all) to 4 (very much). For items that were negatively framed, the scores were reversed for the analysis so that higher scores equate to a good QoL. Total EWB score was calculated as the sum of the 6 items and ranged from 0 to 24, where higher score indicated better emotional well-being related QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively. | Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization | No |
| Secondary | Change From Baseline in Functional Well-Being (FWB) Sub-scale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study | The FWB subscale assessed functional well-being related QoL in participants with breast cancer. FWB subscale comprised of 7 items (able to work, work fulfilled, able to enjoy life, acceptance of illness, sleeping well, enjoyed normal fun activities, contented with QoL). Participants indicated how true a statement had been for them using a 5-point scale from 0 (not at all) to 4 (very much). Total FWB score was calculated as the sum of the 7 items and ranged from 0 to 28, where higher score indicated better functional well-being related QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively. | Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization | No |
| Secondary | Change From Baseline in Breast Cancer Subscale (BCS) Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study | The BCS subscale assessed health related QoL in participants with breast cancer. BCS subscale comprised of 9 items (short of breath, self-conscious dress, tender/swollen arms, sexually attractive, bothered by hair loss, worried about familial risk, worried about family stress, bothered by weight change, able to feel like a woman). Participants indicated how true a statement had been for them using a 5-point scale from 0 (not at all) to 4 (very much). For items that were negatively framed, the scores were reversed for the analysis so that higher scores equated to a good QoL. Total BCS score was calculated as the sum of the 9 items and ranged from 0 to 36, where higher score indicated better QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively. | Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization | No |
| Secondary | Number of Participants With Severe Endocrine Symptoms: QoL Sub-study | Participants indicated prevalence of an endocrine subscale items using a 5-point scale, where 0 (not at all), 1 (a little bit), 2 (somewhat), 3 (quite a bit), 4 (very much). Endocrine items were grouped in five categories vasomotor (hot flushes, cold sweats, night sweats, sleeping difficulties), neuropsychological (lack of energy, nervous feeling, lightheaded/dizzy, headaches, mood swings, feeling irritable), gastrointestinal symptoms (nausea, gained weight, vomiting, diarrhea, bloated feeling), gynecological symptoms (vaginal discharge, vaginal irritation, vaginal bleeding, vaginal dryness, discomfort with intercourse, lost interest in sex, breast tenderness) and other symptoms (pain, feeling ill, side effects). Number of participants who reported severe endocrine symptoms (defined as response categories "quite a bit" and "very much") were presented. | Baseline up to 24 months after randomization | No |
| Secondary | Percentage of Participants With Endometrial Thickness Greater Than or Equal to (>=) 5 Millimeter (mm): Endometrial Sub-study | Endometrial thickness was assessed using transvaginal ultrasound examination. 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively. | 6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment | Yes |
| Secondary | Endometrial Thickness: Endometrial Sub-study | Endometrial thickness was assessed using transvaginal ultrasound examination. 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively. | Baseline, 6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment | Yes |
| Secondary | Uterine and Overall Ovary Volume: Endometrial Sub-study | Uterine volume (UV) and ovarian volume was estimated using ultrasonography. Uterine volume = (longitudinal diameter * transverse diameter * anteroposterior diameter of uterus)/(2*1000). Ovary volume = [(longitudinal diameter * transverse diameter * anteroposterior diameter of ovary) * 3.14]/(6*1000). Overall ovary volume (OV) is calculated as the sum of the right and left ovary volume. 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively. | 6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment | Yes |
| Secondary | Number of Participants With Polyps, Fibroids and Ovarian Cysts: Endometrial Sub-study | Number of participants with presence of polyps (POL) and fibroids (FIB) at post-baseline time points compared to the baseline (BL) status of 'yes', 'no' or 'missing' (that is, participants reporting POL/FIB at post-baseline time points who had yes, no or missing POL/FIB status at baseline, respectively) were presented. Result for number of participants with ovarian cysts was not analyzed at post-baseline time points as very few participants reported ovarian cysts at baseline. | 6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment | Yes |
| Secondary | Percentage of Participants With at Least 1 Gynecological Symptoms: Endometrial Sub-study | Gynecological symptoms included bleeding/spotting, pelvic pain, leucorrhoea and vaginal itching. | Baseline up to 24 months post-treatment | Yes |
| Secondary | Number of Participants With Histological Findings: Endometrial Sub-study | Baseline up to 24 months post-treatment | Yes |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT05558917 -
Comparison Between PECS BLOCK 2 vs ESP BLOCK in Ocnologic Breast Surgery
|
N/A | |
| Active, not recruiting |
NCT03664778 -
Abbreviated Breast MRI After Cancer Treatment
|
||
| Recruiting |
NCT03144622 -
18F-FSPG PET/CT Imaging in Patients With Cancers
|
||
| Completed |
NCT05452499 -
Pain Neuroscience Education and Therapeutic Exercise as a Treatment for Breast Cancer Survivors Living With Sequelae
|
N/A | |
| Active, not recruiting |
NCT04568902 -
Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
|
Phase 1 | |
| Completed |
NCT02860585 -
Evaluation of Survival in Patients With Metastatic Breast Cancer Receiving High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation
|
N/A | |
| Completed |
NCT04059809 -
Photobiomodulation for Breast Cancer Radiodermatitis
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03698942 -
Delphinus SoftVue™ ROC Reader Study
|
||
| Completed |
NCT00092950 -
Exercise in Women at Risk for Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04123704 -
Sitravatinib in Metastatic Breast Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT02151071 -
The Breast Surgery EnLight and LightPath Imaging System Study
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02934360 -
TR(ACE) Assay Clinical Specimen Study
|
N/A | |
| Active, not recruiting |
NCT02950064 -
A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
|
Phase 1 | |
| Not yet recruiting |
NCT02876848 -
A Novel E-Health Approach in Optimizing Treatment for Seniors (OPTIMUM Study)
|
N/A | |
| Completed |
NCT02931552 -
Nuevo Amanecer II: Translating a Stress Management Program for Latinas
|
N/A | |
| Recruiting |
NCT02547545 -
Breast Cancer Chemotherapy Risk Prediction Mathematical Model
|
N/A | |
| Completed |
NCT02303366 -
Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475
|
Phase 1 | |
| Completed |
NCT02518477 -
Preventive Intervention Against Lymphedema After Breast Cancer Surgery
|
N/A | |
| Completed |
NCT02652975 -
Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium
|
N/A |